LENZ Therapeutics Inc
For the period ended Mar 31, 2024. Filed May 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 8, 2024
LENZ$4.10-4.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(in thousands, except for shares and par value)
| March 31, 2024 | December 31, 2023 | |
|---|---|---|
| (unaudited) | ||
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $200,357 | $35,140 |
| Marketable securities | 12,922 | 30,654 |
| Prepaid expenses and other current assets | 3,281 | 1,450 |
| Restricted cash | 114 | — |
| Total current assets | 216,674 | 67,244 |
| Property and equipment, net | 49 | 54 |
| Operating lease right-of-use asset | 578 | 318 |
| Deferred offering costs | — | 2,739 |
| Security deposit | 21 | 21 |
| Total assets | $217,322 | $70,376 |
| Liabilities, convertible preferred and common stock and stockholders’ equity (deficit) | ||
| Current liabilities: | ||
| Accounts payable | $7,131 | $5,711 |
| Accrued liabilities | 11,757 | 12,803 |
| Total current liabilities | 18,888 | 18,514 |
| Operating lease liability, net | 156 | 192 |
| Other noncurrent liabilities | 111 | 121 |
| Preferred stock warrants liability | — | 871 |
| Total liabilities | 19,155 | 19,698 |
| Commitments and contingencies (Note 6) | ||
| Convertible preferred and common stock: | ||
| Series A convertible preferred stock, par value of $0.001 per share; no shares and 22,791,777 shares authorized at March 31, 2024 and December 31, 2023, respectively; no shares and 21,977,282 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | — | 44,621 |
| Series A-1 convertible preferred stock, par value of $0.001 per share; no shares and 2,950,548 shares authorized at March 31, 2024 and December 31, 2023, respectively; no shares and 2,950,548 issued and outstanding at March 31, 2024 and December 31, 2023, respectively | — | 9,893 |
| Series B convertible preferred stock, par value of $0.001 per share; no shares and 28,019,181 shares authorized at March 31, 2024 and December 31, 2023, respectively; no shares and 28,019,181 issued and outstanding at March 31, 2024 and December 31, 2023, respectively | — | 82,976 |
| Class B convertible common stock, par value of $0.001 per share; no shares and 2,744,184 shares authorized at March 31, 2024 and December 31, 2023, respectively; no shares and 2,744,184 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | — | 5,900 |
| Total convertible preferred and common stock | — | 143,390 |
| Stockholders' equity (deficit) (1): | ||
| Common stock, par value of $0.00001 per share; 300,000,000 and 16,017,929 shares authorized at March 31, 2024 and December 31, 2023, respectively, 25,534,451 and 2,004,783 shares issued at March 31, 2024 and December 31, 2023, respectively, and 25,500,130 and 1,969,360 shares outstanding at March 31, 2024 and December 31, 2023, respectively | — | 10 |
|---|---|---|
| Additional paid-in capital | 310,061 | 2,517 |
| Accumulated deficit | (111,893) | (95,245) |
| Accumulated other comprehensive income (loss) | (1) | 6 |
| Total stockholders’ equity (deficit) | 198,167 | (92,712) |
| Total liabilities, convertible preferred and common stock and stockholders’ equity (deficit) | $217,322 | $70,376 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.